Ingenia Therapeutics: Files for US Phase 1/2a trial of IGT303
AI reading
★★★ Bullish · Material event
Files for US IND
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
🤖 9/28 Why the stock moved
Ingenia Therapeutics gains momentum on drug development milestones and US IND filing.
Ingenia Therapeutics confirms upcoming milestone payments and ongoing US IND filing, while shares trade flat as institutional and foreign buying offsets retail selling.
Other filings by Ingenia Therapeutics
For information only. Not investment advice.